Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.
Yuen et al. • 2017 • J Endocr Soc. 2017;1(4):237-246.
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 143 entries already.
Entries by jeremiah@devisedesigns.com
The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness.
Moraitis et al. • 2017 • J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):114-120.
Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome.
Moraitis AG, Auchus RJ. • 2016 • Case Rep Endocrinol. 2016;2016:8453801.
New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.
Pineau et al. • 2016 • Neurobiol Aging. 2016;45:109-122.
Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis
Steffensen et al • 2016 • European Journal of Endocrinology
Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study
Costa et al • 2016 • J Diabetes Complications.
Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals.
Vendruscolo et al. • 2015 • J Clin Invest. 2015;125(8):3193-7.
Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome.
Yuen et al. • 2015 • Endocr Pract. 2015;21(10):1087-92.
Mifepristone and Cushing syndrome: A commentary.
Kennedy L. • 2015 • Endocr Pract. 2015;21(10):1175-7.